Press Release Specialty Care growth, strong launch uptake of Beyfortus and ALTUVIIIO drive solid Q3 results ® ® Paris, October 27, 2023 Q3 2023 sales growth of 3.2% at CER and business EPS decrease of 2.1% at CER (1) Key R&D milestones and regulatory achievements in Q3 Progress on Corporate Social Responsibility strategy in Q3 • Sanofi Global Health Unit: first deliveries of cardio-metabolic products under the Impact brand to the Republic of Djibouti and to global non-governmental organizations Full-year 20 ...

Jo Walton Apologies for that. I just have two questions, please. I noticed that Dietmar isn't on the Executive Committee just looking at the -- on your website. I wonder if you could tell us when you're going to be in a position to announce the head -- a new permanent head of R&D? And could I just ask related, another R&D-related question. It's a couple of years now since you bought Title IP for the targeted delivery CAR-T, certain cell types? I wonder -- this area still looks to be facing real challenges. ...

Exhibit 99.1 | | TABLE OF CONTENTS | | | --- | --- | --- | | 1. | CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS | 2 | | | CONSOLIDATED BALANCE SHEETS – ASSETS | 2 | | | CONSOLIDATED BALANCE SHEETS — SHAREHOLDERS' EQUITY AND LIABILITIES | 3 | | | CONSOLIDATED INCOME STATEMENTS | 4 | | | CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | 5 | | | CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY | 6 | | | CONSOLIDATED STATEMENTS OF CASH FLOWS | 8 | | | NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL ...

And just 2 quick ones. Firstly, just on the oral TNF again. Obviously, one of the indications where we are seeing OTNF still be used and actually not facing the same competition is HS, where I think you've also got some other programs looking at as well. I'm curious, I guess, why necessarily the focus on psoriasis, which is a pretty competitive market and I guess not some other potential statements as there are where perhaps less competition about the more amenable there for you to be an early entrant. Thom ...

Exhibit 99.2 Press Release Business net income (a non-IFRS financial measure) for the year ended December 31, 2022 is unchanged, as is the amount of the dividend proposed by the Board of Directors held on February 2, 2023. Updated IFRS figures for 2022 Financial Statements1 | | Q4 2022 | Change | Change | 2022 | Change | Change | | --- | --- | --- | --- | --- | --- | --- | | | | | at CER | | | at CER | | IFRS net sales reported | €10,725m | +7.3% | +2.6% | €42,997m | +13.9% | +7.0% | | IFRS net income repor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

Sanofi SA (NASDAQ:SNY) Q4 2022 Results Conference Call February 3, 2023 8:00 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - EVP, Specialty Care and President, North America Thomas Triomphe - EVP, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - EVP and CFO John Reed - EVP and Global Head, R&D Conference Call Participants Graham Parry - BofA Peter Welford - Jefferies Richard Vosser - JPMor ...

Press Release Exhibit 99.2 Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma Paris and Tarrytown, N.Y. September 5, 2022. Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncont ...

Exhibit 99.1 | | TABLE OF CONTENTS | | --- | --- | | 1. | CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 | | | CONSOLIDATED BALANCE SHEETS – ASSETS 2 | | | CONSOLIDATED BALANCE SHEETS — SHAREHOLDERS' EQUITY AND LIABILITIES 3 | | | 4 CONSOLIDATED INCOME STATEMENTS | | | CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 | | | CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY 6 | | | CONSOLIDATED STATEMENTS OF CASH FLOWS 9 | | | NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE ...

Exhibit 99.1 Information Statement DISTRIBUTION OF SHARES OF EUROAPI TO THE SHAREHOLDERS OF SANOFI This information statement is intended to provide shareholders of Sanofi ("Sanofi") in specified jurisdictions other than France (as set forth under "Notice to Prospective Shareholders of EUROAPI", the "Jurisdictions") with information relating to the proposed pro rata distribution of approximately 58% of the outstanding shares of the EUROAPI company ("EUROAPI" or the "Company") by Sanofi to its shareholders ( ...